Linked Data API

Show Search Form

Search Results

1128007
registered interest false more like this
date remove filter
answering body
Department for Environment, Food and Rural Affairs more like this
answering dept id 13 more like this
answering dept short name Environment, Food and Rural Affairs more like this
answering dept sort name Environment, Food and Rural Affairs more like this
hansard heading Fire Resistant Materials more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask Her Majesty's Government, further to the Written Answer by Lord Henley on 20 May (HL15634), whether DecaBDE is the same chemical as DecaPBDE; and whether production and use of DecaPBDE continues in the UK. more like this
tabling member printed
The Countess of Mar more like this
uin HL15892 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-06-04more like thismore than 2019-06-04
answer text <p>Polybrominated diphenyl ether (PBDE) is a group of chemicals consisting of brominated hydrocarbons, of which decabromodiphenyl ether (DecaBDE) is one. When the term DecaPBDE is used in literature it usually refers to DecaBDE.</p><p> </p><p>The UK ceased production of DecaBDE in 1996 and its use has declined sharply since then. It has been banned under the UN Stockholm Convention on Persistent Organic Pollutants since December 2018 and this will be reflected in the revision to Regulation (EC) No 850/2004 on Persistent Organic Pollutants and also under the European chemical regulation regime, REACH, since March 2019.</p> more like this
answering member printed Lord Gardiner of Kimble more like this
question first answered
less than 2019-06-04T14:24:04.047Zmore like thismore than 2019-06-04T14:24:04.047Z
answering member
4161
label Biography information for Lord Gardiner of Kimble more like this
tabling member
1861
label Biography information for The Countess of Mar more like this
1128008
registered interest false more like this
date remove filter
answering body
Department for Business, Energy and Industrial Strategy more like this
answering dept id 201 more like this
answering dept short name Business, Energy and Industrial Strategy more like this
answering dept sort name Business, Energy and Industrial Strategy more like this
hansard heading Furniture: Fire Resistant Materials more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask Her Majesty's Government, further to the Written Answer by Lord Gardiner of Kimble on 11 September 2018 (HL10265), whether the volumes of DecaBDE in existing upholstered furniture have been established; and what procedures are in place to safely dispose of such furniture. more like this
tabling member printed
The Countess of Mar more like this
uin HL15893 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-06-05more like thismore than 2019-06-05
answer text <p>The Government does not hold information on the volumes of DecaBDE in existing upholstered furniture. The Government is working with stakeholders and experts to assess the best routes for disposal of waste containing DecaBDE to protect the environment and human health.</p> more like this
answering member printed Lord Henley more like this
question first answered
less than 2019-06-05T15:52:23.443Zmore like thismore than 2019-06-05T15:52:23.443Z
answering member
2616
label Biography information for Lord Henley more like this
tabling member
1861
label Biography information for The Countess of Mar more like this
1128009
registered interest false more like this
date remove filter
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Medical Treatments: Children more like this
house id 2 more like this
legislature
25277
pref label House of Lords more like this
question text To ask Her Majesty's Government what processes are in place to safeguard children with chronic fatigue syndrome and other disorders whose parents have enrolled them on Lightning Process courses; and what evaluation has been undertaken of the (1) benefits, and (2) harms, to those children who have participated in such courses. more like this
tabling member printed
The Countess of Mar more like this
uin HL15894 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-06-05more like thismore than 2019-06-05
answer text <p>The Lightning Process (LP) is not offered as a part of the chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) standard treatments on the National Health Service. Subject to the nature of the safeguarding concerns, issues should be directed to the relevant professional regulator, should the practitioner be a member of a registered profession; the local authority (trading standards office or children’s service), if false claims are being made about the effectiveness of the treatment or welfare of a child is a concern; or the police, if a crime is involved.</p><p>The LP involves a course of three half-days of training aiming to teach participants how to use their brain to improve their body's health.</p><p>A randomised controlled trial with 100 adolescents aged 12-18 was undertaken by researchers in Bristol. Participants were randomised into two groups: those who received standard CFS/ME treatment and those who received the standard treatment plus the LP.</p><p>Researchers found those who received the LP had better physical function, were less tired and less anxious after six months. At 12 months, they had further improvement in physical function, and improved depression scores and school attendance. This research trial had several limitations as set out in the peer reviewed journal article. This was a very small trial and so it would need to be repeated in a much larger group to demonstrate more generalisable findings. Participants were not blinded so their self-reported outcomes might have been biased, for example participants may have been more likely to report positive outcomes because they knew they were getting additional therapy in the LP group. Of all those eligible to participate in the trial, fewer than 30% agreed to take part. Participants in the trial did not have any serious adverse events attributable to either LP or usual care. LP therapy was given in addition to the usual CFS/ME care as a no-treatment control group was not deemed ethical, therefore it cannot be suggested as a replacement for current specialised medical care.</p><p>Independent ethical review ensures that participant safety is at the centre of all research. In the United Kingdom, review by an ethics committee is one of a series of safeguards intended to protect the people taking part in the research. The operating procedure for trials in the UK has inbuilt safeguards designed to protect patients from harm in the event an intervention is ineffective or potentially harmful. Participants are free to withdraw from a study at any time.</p><p> </p>
answering member printed Baroness Blackwood of North Oxford more like this
question first answered
less than 2019-06-05T16:40:17.41Zmore like thismore than 2019-06-05T16:40:17.41Z
answering member
4019
label Biography information for Baroness Blackwood of North Oxford more like this
tabling member
1861
label Biography information for The Countess of Mar more like this